journal
MENU ▼
Read by QxMD icon Read
search

Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology

journal
https://www.readbyqxmd.com/read/30625041/the-oncology-hospital-at-home
#1
Nathan R Handley, Justin E Bekelman
No abstract text is available yet for this article.
January 9, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30625040/population-based-assessment-of-the-association-between-magnetic-resonance-imaging-background-parenchymal-enhancement-and-future-primary-breast-cancer-risk
#2
Vignesh A Arasu, Diana L Miglioretti, Brian L Sprague, Nila H Alsheik, Diana S M Buist, Louise M Henderson, Sally D Herschorn, Janie M Lee, Tracy Onega, Garth H Rauscher, Karen J Wernli, Constance D Lehman, Karla Kerlikowske
PURPOSE: To evaluate comparative associations of breast magnetic resonance imaging (MRI) background parenchymal enhancement (BPE) and mammographic breast density with subsequent breast cancer risk. PATIENTS AND METHODS: We examined women undergoing breast MRI in the Breast Cancer Surveillance Consortium from 2005 to 2015 (with one exam in 2000) using qualitative BPE assessments of minimal, mild, moderate, or marked. Breast density was assessed on mammography performed within 5 years of MRI...
January 9, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30625039/prorepair-b-a-prospective-cohort-study-of-the-impact-of-germline-dna-repair-mutations-on-the-outcomes-of-patients-with-metastatic-castration-resistant-prostate-cancer
#3
Elena Castro, Nuria Romero-Laorden, Angela Del Pozo, Rebeca Lozano, Ana Medina, Javier Puente, Josep Maria Piulats, David Lorente, Maria Isabel Saez, Rafael Morales-Barrera, Enrique Gonzalez-Billalabeitia, Ylenia Cendón, Iciar García-Carbonero, Pablo Borrega, M José Mendez Vidal, Alvaro Montesa, Paz Nombela, Eva Fernández-Parra, Aránzazu Gonzalez Del Alba, José Carlos Villa-Guzmán, Kristina Ibáñez, Alejo Rodriguez-Vida, Lorena Magraner-Pardo, Begoña Perez-Valderrama, Elena Vallespín, Enrique Gallardo, Sergio Vazquez, Colin C Pritchard, Pablo Lapunzina, David Olmos
PURPOSE: Germline mutations in DNA damage repair (DDR) genes are identified in a significant proportion of patients with metastatic prostate cancer, but the clinical implications of these genes remain unclear. This prospective multicenter cohort study evaluated the prevalence and effect of germline DDR (gDDR) mutations on metastatic castration-resistance prostate cancer (mCRPC) outcomes. PATIENTS AND METHODS: Unselected patients were enrolled at diagnosis of mCRPC and were screened for gDDR mutations in 107 genes...
January 9, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30620670/safe-handling-of-hazardous-drugs-asco-standards
#4
Paul Celano, Christopher A Fausel, Erin B Kennedy, Tim M Miller, Thomas K Oliver, Ray Page, Jeffery C Ward, Robin T Zon
PURPOSE: To provide 2019 ASCO standards on the safe handling of hazardous drugs. METHODS: An Expert Panel was formed, and a systematic review of the literature on closed system transfer devices was performed to May 2017 using PubMed. The Cochrane Database of Systematic Reviews, PubMed, and Google Scholar were used to search for studies of medical surveillance and external ventilation/health effects of exposure to vapors to November 2017. Available standards were considered for endorsement...
January 8, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30620669/nivolumab-for-relapsed-refractory-diffuse-large-b-cell-lymphoma-in-patients-ineligible-for-or-having-failed-autologous-transplantation-a-single-arm-phase-ii-study
#5
Stephen M Ansell, Monique C Minnema, Peter Johnson, John M Timmerman, Philippe Armand, Margaret A Shipp, Scott J Rodig, Azra H Ligon, Margaretha G M Roemer, Nishitha Reddy, Jonathon B Cohen, Sarit Assouline, Michelle Poon, Manish Sharma, Kazunobu Kato, Selda Samakoglu, Anne Sumbul, Andrew Grigg
PURPOSE: Treatment options are limited for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL). Tumor cells can exploit the programmed death-1 checkpoint pathway to evade immune surveillance. In the current study, we evaluated the efficacy and safety of programmed death-1 blockade by nivolumab in patients with relapsed/refractory DLBCL. METHODS: In this phase II, open-label study, patients with relapsed/refractory DLBCL who were ineligible for autologous hematopoietic cell transplantation (auto-HCT) or who had experienced failure with auto-HCT received nivolumab 3 mg/kg every 2 weeks...
January 8, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30620668/updated-analysis-of-keynote-024-pembrolizumab-versus-platinum-based-chemotherapy-for-advanced-non-small-cell-lung-cancer-with-pd-l1-tumor-proportion-score-of-50-or-greater
#6
Martin Reck, Delvys Rodríguez-Abreu, Andrew G Robinson, Rina Hui, Tibor Csőszi, Andrea Fülöp, Maya Gottfried, Nir Peled, Ali Tafreshi, Sinead Cuffe, Mary O'Brien, Suman Rao, Katsuyuki Hotta, Kristel Vandormael, Antonio Riccio, Jing Yang, M Catherine Pietanza, Julie R Brahmer
PURPOSE: In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations. We report an updated OS and tolerability analysis, including analyses adjusting for potential bias introduced by crossover from chemotherapy to pembrolizumab...
January 8, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30615550/survival-outcomes-of-younger-patients-with-mantle-cell-lymphoma-treated-in-the-rituximab-era
#7
James N Gerson, Elizabeth Handorf, Diego Villa, Alina S Gerrie, Parv Chapani, Shaoying Li, L Jeffrey Medeiros, Michael I Wang, Jonathon B Cohen, Oscar Calzada, Michael C Churnetski, Brian T Hill, Yazeed Sawalha, Francisco J Hernandez-Ilizaliturri, Shalin Kothari, Julie M Vose, Martin A Bast, Timothy S Fenske, Swapna Narayana Rao Gari, Kami J Maddocks, David Bond, Veronika Bachanova, Bhaskar Kolla, Julio Chavez, Bijal Shah, Frederick Lansigan, Timothy F Burns, Alexandra M Donovan, Nina Wagner-Johnston, Marcus Messmer, Amitkumar Mehta, Jennifer K Anderson, Nishitha Reddy, Alexandra E Kovach, Daniel J Landsburg, Martha Glenn, David J Inwards, Reem Karmali, Jason B Kaplan, Paolo F Caimi, Saurabh Rajguru, Andrew Evens, Andreas Klein, Elvira Umyarova, Bhargavi Pulluri, Jennifer E Amengual, Jennifer K Lue, Catherine Diefenbach, Richard I Fisher, Stefan K Barta
PURPOSE: Mantle cell lymphoma (MCL) is a B-cell lymphoma characterized by cyclin D1 expression. Autologous hematopoietic cell transplantation (AHCT) consolidation after induction chemotherapy is often used for eligible patients; however, the benefit remains uncertain in the rituximab era. Herein we retrospectively assessed the impact of AHCT consolidation on survival in a large cohort of transplantation-eligible patients age 65 years or younger. PATIENTS AND METHODS: We retrospectively studied transplantation-eligible adults age 65 years or younger with newly diagnosed MCL treated between 2000 and 2015...
January 7, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30615549/induction-chemotherapy-response-as-a-guide-for-treatment-optimization-in-sinonasal-undifferentiated-carcinoma
#8
Moran Amit, Ahmed S Abdelmeguid, Teemaranawich Watcherporn, Hideaki Takahashi, Samantha Tam, Diana Bell, Renata Ferrarotto, Bonnie Glisson, Michael E Kupferman, Dianna B Roberts, Shirley Y Su, Shaan M Raza, Franco DeMonte, Ehab Y Hanna
PURPOSE: Multimodal therapy is a well-established approach for the treatment of sinonasal undifferentiated carcinoma (SNUC); however, the optimal sequence of the various treatments modalities is yet to be determined. This study aimed to assess the role of induction chemotherapy (IC) in guiding definitive therapy in patients with SNUC. METHODS: Ninety-five previously untreated patients diagnosed with SNUC and treated between 2001 and 2018 at The University of Texas MD Anderson Cancer Center were included in the analysis...
January 7, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30608896/functional-repair-assay-for-the-diagnosis-of-constitutional-mismatch-repair-deficiency-from-non-neoplastic-tissue
#9
Andrew Y Shuen, Stella Lanni, Gagan B Panigrahi, Melissa Edwards, Lisa Yu, Brittany B Campbell, Ariane Mandel, Cindy Zhang, Nataliya Zhukova, Musa Alharbi, Mark Bernstein, Daniel C Bowers, Sara Carroll, Kristina A Cole, Shlomi Constantini, Bruce Crooks, Rina Dvir, Roula Farah, Nobuko Hijiya, Ben George, Theodore W Laetsch, Valerie Larouche, Scott Lindhorst, Rebecca C Luiten, Vanan Magimairajan, Gary Mason, Warren Mason, Oz Mordechai, Naureen Mushtaq, Garth Nicholas, Michael Oren, Laura Palma, Luis Alberto Pedroza, Jagadeesh Ramdas, David Samuel, Kami Wolfe Schneider, Andrea Seeley, Kara Semotiuk, Ashraf Shamvil, David Sumerauer, Helen Toledano, Patrick Tomboc, Margaret Wierman, An Van Damme, Yi-Yen Lee, Michal Zapotocky, Eric Bouffet, Carol Durno, Melyssa Aronson, Steve Gallinger, William D Foulkes, David Malkin, Uri Tabori, Christopher E Pearson
PURPOSE: Constitutional mismatch repair deficiency (CMMRD) is a highly penetrant cancer predisposition syndrome caused by biallelic mutations in mismatch repair (MMR) genes. As several cancer syndromes are clinically similar, accurate diagnosis is critical to cancer screening and treatment. As genetic diagnosis is confounded by 15 or more pseudogenes and variants of uncertain significance, a robust diagnostic assay is urgently needed. We sought to determine whether an assay that directly measures MMR activity could accurately diagnose CMMRD...
January 4, 2019: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30592644/sex-differences-in-efficacy-and-toxicity-of-systemic-cancer-treatments-role-of-the-microbiome
#10
Laura Pala, Luigi Nezi, Tommaso De Pas, Elisabetta Pennacchioli, Emilia Cocorocchio, Pierfrancesco Ferrucci, Fabio Conforti, Aron Goldhirsch
No abstract text is available yet for this article.
December 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30592643/prostate-cancer-radiotherapy-an-evolving-paradigm-that-should-also-include-high-dose-rate-monotherapy
#11
John David, Mitchell Kamrava
No abstract text is available yet for this article.
December 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30592642/reply-to-j-david-et-al
#12
Jarad Martin, Himu Lukka, Charles Catton
No abstract text is available yet for this article.
December 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30592641/reply-to-h-j-a-adams-et-al
#13
Qian Shi, Christopher R Flowers
No abstract text is available yet for this article.
December 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30592640/trk-fusion-cancers-in-children-a-clinical-review-and-recommendations-for-screening
#14
Catherine M Albert, Jessica L Davis, Noah Federman, Michela Casanova, Theodore W Laetsch
Chromosomal translocations involving the NTRK1, NTRK2, and NTRK3 genes (TRK fusions), which encode the neurotrophin tyrosine kinase receptors TRKA, TRKB, and TRKC, can result in constitutive activation and aberrant expression of TRK kinase. Certain cancers almost universally harbor TRK fusions, including infantile fibrosarcoma, cellular congenital mesoblastic nephroma, secretory breast cancer, and mammary analog secretory carcinoma of the salivary gland. TRK fusions have also been identified at lower frequencies across a broad range of other pediatric cancers, including undifferentiated sarcomas, gliomas, papillary thyroid cancers, spitzoid neoplasms, inflammatory myofibroblastic tumors, and acute leukemias...
December 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30592639/standardized-definition-of-progression-free-survival-in-diffuse-large-b-cell-lymphoma-is-urgently-needed
#15
Hugo J A Adams, Thomas C Kwee
No abstract text is available yet for this article.
December 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30592638/reply-to-l-pala-et-al
#16
Anna Dorothea Wagner, Berna Özdemir, Chantal Csajka
No abstract text is available yet for this article.
December 28, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30589600/neoadjuvant-degarelix-versus-triptorelin-in-premenopausal-patients-who-receive-letrozole-for-locally-advanced-endocrine-responsive-breast-cancer-a-randomized-phase-ii-trial
#17
Silvia Dellapasqua, Kathryn P Gray, Elisabetta Munzone, Daniela Rubino, Lorenzo Gianni, Harriet Johansson, Giuseppe Viale, Karin Ribi, Jürg Bernhard, Roswitha Kammler, Rudolf Maibach, Manuela Rabaglio-Poretti, Barbara Ruepp, Angelo Di Leo, Alan S Coates, Richard D Gelber, Meredith M Regan, Aron Goldhirsch, Marco Colleoni
PURPOSE: To evaluate endocrine activity in terms of ovarian function suppression (OFS) of degarelix (a gonadotropin-releasing hormone [GnRH] antagonist) versus triptorelin (a GnRH agonist) in premenopausal patients receiving letrozole as neoadjuvant endocrine therapy for breast cancer. PATIENTS AND METHODS: Premenopausal women with stage cT2 to 4b, any N, M0; estrogen receptor and progesterone receptor greater than 50%; human epidermal growth factor receptor 2-negative breast cancer were randomly assigned to triptorelin 3...
December 27, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30589599/clonal-hematopoiesis-of-indeterminate-potential
#18
Steffen Boettcher, Benjamin L Ebert
No abstract text is available yet for this article.
December 27, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30586316/phase-i-dose-escalation-study-of-once-weekly-or-once-every-two-weeks-administration-of-high-dose-sunitinib-in-patients-with-refractory-solid-tumors
#19
Maria Rovithi, Sophie L Gerritse, Richard J Honeywell, Albert J Ten Tije, Rita Ruijter, Godefridus J Peters, Jens Voortman, Mariette Labots, Henk M W Verheul
PURPOSE: Dose and schedule optimization of treatment with tyrosine kinase inhibitors is of utmost importance. On the basis of preclinical data, a phase I clinical trial of once weekly or once every 2 weeks administration of high-dose sunitinib in patients with refractory solid malignancies was conducted. PATIENTS AND METHODS: Patients with advanced cancer refractory to standard treatment were eligible. With use of a standard 3 + 3 phase I design, patients received escalating doses of sunitinib, in 100 mg increments, starting at 200 mg once weekly...
December 26, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/30576269/detection-of-relapse-by-tumor-markers-versus-imaging-in-children-and-adolescents-with-nongerminomatous-malignant-germ-cell-tumors-a-report-from-the-children-s-oncology-group
#20
Adriana Fonseca, Caihong Xia, Armando J Lorenzo, Mark Krailo, Thomas A Olson, Farzana Pashankar, Marcio H Malogolowkin, James F Amatruda, Deborah F Billmire, Carlos Rodriguez-Galindo, A Lindsay Frazier, Furqan Shaikh
PURPOSE: To investigate relapse detection methods among children and adolescents with nongerminomatous malignant germ cell tumors (MGCTs) and to determine whether tumor markers alone might be sufficient for surveillance. METHODS: We retrospectively reviewed all patients enrolled in a phase III, single-arm trial for low-risk and intermediate-risk MGCTs. The method used to detect relapse was assessed based on case report forms, tumor markers, imaging, and pathology reports...
December 21, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
journal
journal
20146
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"